The decision to reanimate an Alzheimer's disease program that died eight months earlier gave investors a lot to think about.
News & Analysis: Biogen
Which stock wins in a head-to-head matchup between these two big biotechs?
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
The biotech popped 30% after the extremely unusual revival of an Alzheimer's treatment that had looked like a failure at first.
Investors were pleasantly surprised by an unexpected turnaround in aducanumab's clinical trial data, but how justified is the market's optimism?
Can these recent highfliers keep climbing?
Biogen's risk-to-reward ratio may now be too compelling to pass up.
The reassessment of a failed Alzheimer's disease study looks more like an act of desperation than a clinical triumph.
A drug once thought of as dead could be rising from the ashes. Does Biogen's shocking news make the stock a buy now?
One biotech zoomed 26% higher, while a prominent rideshare company saw a more-than-6% boost.